In an industry survey report conducted by ArisGlobal, a leading life sciences technology company, an interesting trend in the pharmaceutical industry has been revealed. The report indicates a strong commitment among pharmaceutical organizations to embrace artificial intelligence (AI) and automation in order to revolutionize their safety and regulatory processes. The goal is to bring new drugs to market quickly and cost-efficiently. According to the survey, 60% of companies plan to explore the adoption or increased usage of advanced technologies over the next 18 months.
However, there seems to be a significant gap between the intentions of these organizations and their actual implementation and usage of next-generation technologies. While over 75% of organizations claim to use some form of advanced automation, only 8% have applied next-generation capabilities on a widespread basis. The main challenge lies in integrating the technology into existing infrastructure. Budgetary constraints and poor integration with existing technology have been cited as the biggest obstacles to AI adoption in the life sciences industry. In fact, 54% of participating organizations stated that budget was the main barrier.
Moreover, survey respondents revealed that integrating automation technology with other systems and data has been challenging for more than two-thirds (68%) of them. Overcoming these barriers will be crucial for companies who want to fully benefit from the potential of next-generation technologies. For instance, leveraging real-world data (RWD) for labor-intensive processes such as safety signal detection and validation could open up new opportunities for innovation in patient treatment. Fortunately, the study identified a growing interest in harnessing RWD, with 51% of organizations already connected to some form of RWD and 54% expressing plans to increase its usage.
Emmanuel Belabe, SVP of Customer Success at ArisGlobal, commented on the industry’s ambitions to integrate AI and machine learning into safety and regulatory processes. He mentioned that companies' transitions to intelligent automation will continue to accelerate due to business and operational mandates. Belabe attributed this acceleration to advancements in technology, notably cloud platforms like LifeSphere® from ArisGlobal, which is powered by advanced automation engine NavaX. ArisGlobal has been a trusted collaborator with top pharma companies for over 35 years, helping them stay ahead of what’s possible in terms of technology and strategic alliances, such as partnerships with real-world data providers.
The full ArisGlobal 2024 Industry Survey Report, titled “Life Sciences R&D Transformation: Ambitions for Intelligent Automation & Today’s Reality,” offers a comprehensive analysis of the current state and future outlook of the industry. It is available for download on ArisGlobal’s website.
The survey findings suggest that the pharmaceutical industry is keen to harness the power of AI and automation to streamline their processes and bring innovative treatments to patients more efficiently. While there are challenges to overcome, the potential benefits of these technologies are clear. As the industry continues to evolve, it will be interesting to see how organizations navigate the integration of AI and automation into their operations, ultimately delivering better outcomes for patients around the world.
Use the share button below if you liked it.